Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction
Koen W. Streng(University Medical Center Groningen), Adriaan A. Voors(University Medical Center Groningen), Piotr Ponikowski(Wroclaw Medical University), Gerasimos Filippatos(National and Kapodistrian University of Athens), Hans L. Hillege(University Medical Center Groningen), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Aeilko H. Zwinderman(Amsterdam Neuroscience), Kevin Damman(University Medical Center Groningen), Marco Metra(Vita-Salute San Raffaele University), Chim C. Lang(University of Dundee), Dirk J. van Veldhuisen(University Medical Center Groningen), Leong L. Ng(University of Leicester), Nilesh J. Samani(University of Leicester), Kenneth Dickstein, Peter van der Meer(University Medical Center Groningen), Stefan D. Anker(Bayer (Germany)), Jan F. Nauta(University Medical Center Groningen), John G.F. Cleland(University of Glasgow)
Cited by 204
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k